0.05Open0.01Pre Close1 Volume5 Open Interest5.00Strike Price5.00Turnover194.00%IV115.81%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1071Delta0.1559Gamma46.80Leverage Ratio-0.0044Theta0.0001Rho5.01Eff Leverage0.0011Vega
NRX Pharmaceuticals Stock Discussion
loading zone
NRX Pharmaceuticals (Nasdaq:Nrxp) to Proceed With Two New Drug Applications in 2024; NRX-101 Has Been Returned to the Company for Filing
What is OCU400's market potential? If we take Ocugen's estimates seriously, it is mouthwatering. The biotech projects that OCU400 could earn approval in 2026. Ocugen thinks the therapy could generate between $30 billion and $47 billion in total revenue in the five years after approval. The company's market cap is about $488 million as of this writing. So by any standar...
Catching the attention of the pharmaceutical industry and investors alike, NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage pharmaceutical company, has announced final clinical trial results showcasing a superior safety profile of NRX-101 over lurasidon...
No comment yet